Thermo Fisher Scientific Inc (NYSE:TMO) Director Jim P. Manzi sold 11,318 shares of the stock in a transaction on Friday, August 18th. The stock was sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the transaction, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at 172.57 on Monday. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The firm has a market cap of $67.32 billion, a PE ratio of 30.06 and a beta of 1.06. The stock’s 50 day moving average is $176.71 and its 200-day moving average is $166.56.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. The company had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.03 EPS. Analysts expect that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.45%.

TRADEMARK VIOLATION NOTICE: This report was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/21/insider-selling-thermo-fisher-scientific-inc-tmo-director-sells-1957334-92-in-stock.html.

TMO has been the subject of several recent research reports. Deutsche Bank AG increased their target price on shares of Thermo Fisher Scientific from $163.00 to $188.00 and gave the stock a “buy” rating in a report on Friday, April 28th. BTIG Research increased their target price on shares of Thermo Fisher Scientific from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Barclays PLC set a $175.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 26th. Leerink Swann set a $187.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, April 27th. Finally, Bank of America Corporation increased their target price on shares of Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, May 9th. One research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus price target of $188.56.

Several institutional investors have recently modified their holdings of TMO. Proficio Capital Partners LLC increased its stake in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Cribstone Capital Management LLC increased its stake in Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after buying an additional 50 shares during the period. Shine Investment Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $113,000. Chicago Partners Investment Group LLC acquired a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $108,000. Finally, CWM LLC increased its stake in Thermo Fisher Scientific by 17.0% in the second quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 103 shares during the period. 87.60% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.